NRXS Stock Analysis: Neuraxis | NYSE MKT
Biotechnology | NYSE MKT, USA | Market Cap: 82m USD | 12M Return: 132.4% | US64134X2018 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 675K
Qual. Beats: 0
Rev. Trend: 90.7%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality
NeurAxis, Inc. (NRXS) is a medical technology company. It develops neuromodulation therapies for chronic conditions in both children and adults.
The companys primary product is IB-Stim. This system uses percutaneous electrical nerve field stimulation to treat functional abdominal pain linked to irritable bowel syndrome in patients aged 8-21. This technology falls under the broader medical device sector, which focuses on non-pharmaceutical interventions for health conditions.
NeurAxis sells its products to healthcare providers, including hospitals and clinics. This business model relies on adoption by medical institutions and prescription by healthcare professionals.
Founded in 2011 as Innovative Health Solutions, Inc., the company rebranded to NeurAxis, Inc. in March 2022. It is headquartered in Carmel, Indiana.
For more in-depth analysis, consider exploring further research on ValueRay.
- IB-Stim sales growth drives revenue expansion
- Regulatory approval for new indications expands market
- Reimbursement policy changes impact product accessibility
- Pediatric IBS prevalence influences addressable market
| Net Income: -7.87m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.56 > 0.02 and ΔFCF/TA 31.85 > 1.0 |
| NWC/Revenue: 118.8% < 20% (prev 132.8%; Δ -13.91% < -1%) |
| CFO/TA -0.56 > 3% & CFO -5.62m > Net Income -7.87m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (12.1m) vs 12m ago 42.24% < -2% |
| Gross Margin: 85.56% > 18% (prev 84.83%; Δ 0.73% > 0.5%) |
| Asset Turnover: 62.23% > 50% (prev 45.39%; Δ 16.84% > 0%) |
| Interest Coverage Ratio: -72.63 > 6 (EBIT TTM -7.57m / Interest Expense TTM 104k) |
| A: 0.63 (Total Current Assets 9.41m - Total Current Liabilities 3.10m) / Total Assets 10.00m |
| B: -6.97 (Retained Earnings -69.7m / Total Assets 10.00m) |
| C: -0.89 (EBIT TTM -7.57m / Avg Total Assets 8.54m) |
| D: 2.07 (Book Value of Equity 6.74m / Total Liabilities 3.26m) |
| Altman-Z'' = -22.36 = D |
| DSRI: 2.04 (Receivables 433k/129k, Revenue 5.32m/3.22m) |
| GMI: 0.99 (GM 84.83% / 85.56%) |
| AQI: 0.09 (AQ_t -0.00 / AQ_t-1 -0.04) |
| SGI: 1.65 (Revenue 5.32m / 3.22m) |
| TATA: -0.22 (NI -7.87m - CFO -5.62m) / TA 10.00m) |
| Beneish M = -2.27 (Cap -4..+1) = BBB |
As of October 16, 2026, the stock is trading at USD 7.74 with a total of 1,126,599 shares traded. Over the past week, the price has changed by +14.33%, over one month by +35.79%, over three months by +10.89% and over the past year by +132.43%.
Current recommended Stop Loss: 6.70 (which is 13.4% or 2.2 ATR below the current price).
Neuraxis has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy NRXS.
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 11 | 42.1% |
P/S = 15.4252
P/B = 13.6375
Revenue TTM = 5.32m USD
EBIT TTM = -7.57m USD
EBITDA TTM = -7.50m USD
Long Term Debt = 165k USD (estimated: total debt 279k - short term 115k)
Short Term Debt = 115k USD (from shortTermDebt, last quarter)
Debt = 516k USD (from shortLongTermDebtTotal, last quarter) + Leases 237k
Net Debt = -7.81m USD (calculated: Debt 516k - CCE 8.32m)
Enterprise Value = 74.2m USD (82.0m + Debt 516k - CCE 8.32m)
Interest Coverage Ratio = -72.63 (Ebit TTM -7.57m / Interest Expense TTM 104k)
EV/FCF = -13.17x (Enterprise Value 74.2m / FCF TTM -5.63m)
FCF Yield = -7.59% (FCF TTM -5.63m / Enterprise Value 74.2m)
FCF Margin = -106.0% (FCF TTM -5.63m / Revenue TTM 5.32m)
Net Margin = -148.0% (Net Income TTM -7.87m / Revenue TTM 5.32m)
Gross Margin = 85.56% ((Revenue TTM 5.32m - Cost of Revenue TTM 768k) / Revenue TTM)
Gross Margin QoQ = 85.87% (prev 86.42%)
Tobins Q-Ratio = 7.42 (Enterprise Value 74.2m / Total Assets 10.00m)
Interest Expense / Debt = 20.21% (Interest Expense 104k / Debt 516k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -5.98m (EBIT -7.57m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.04 (Total Current Assets 9.41m / Total Current Liabilities 3.10m)
Debt / Equity = 0.08 (Debt 516k / totalStockholderEquity, last quarter 6.74m)
Debt / EBITDA = 1.04 (negative EBITDA) (Net Debt -7.81m / EBITDA -7.50m)
Debt / FCF = 1.39 (negative FCF - burning cash) (Net Debt -7.81m / FCF TTM -5.63m)
Total Stockholder Equity = 4.54m (last 4 quarters mean from totalStockholderEquity)
RoA = -92.13% (Net Income -7.87m / Total Assets 10.00m)
RoE = -173.3% (Net Income TTM -7.87m / Total Stockholder Equity 4.54m)
RoCE = -160.9% (out of range, set to none) (EBIT -7.57m / Capital Employed (Equity 4.54m + L.T.Debt 165k))
RoIC = -88.67% (negative operating profit) (NOPAT -5.98m / Invested Capital 6.75m)
WACC = 10.07% (E(82.0m)/V(82.5m) * Re(10.03%) + D(516k)/V(82.5m) * Rd(20.21%) * (1-Tc(0.21)))
Discount Rate = 10.03% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.93 | Cagr: 31.45%
[DCF] Fair Price = unknown (Cash Flow -5.63m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.77 | # QB: 0
Revenue Correlation: 90.74 | Revenue CAGR: 30.52% | SUE: -0.00 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.21 | Chg30d=+0.00% | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.76 | Chg30d=+0.00% | Revisions=-25% | GrowthEPS=+13.5% | GrowthRev=+132.5%
EPS next Year (2027-12-31): EPS=-0.27 | Chg30d=+0.00% | Revisions=-25% | GrowthEPS=+64.5% | GrowthRev=+138.5%